sale slightli exceed our/street
estim ep top our/street led greater fx/lower tax
rate vs estim sale growth calendar line market
lower america off-set better emea asiapac america
believ differenti anomal note differ comp launch
myday toric expect driver ep guidanc increas
midpoint led higher fx ep also includ expect paragard iud acquisit
accret tax rate also slightli better rate rise
base manag current estim around tax reform rate
perform valuat
coopervis grew pro forma estim across categori
growth continu driven sihi daili clariti myday well
biofin sihi grew solid pf growth led asiapac
emea america growth america myday toric launch
expect drive growth daili
vision market grew y/i line market saw strong
above-market growth emea asia-pac manag note
below-market growth america vs calendar owe difficult
comp manag maintain target market
surgic sale fell pro forma previous commun inventori de-
stock paragard manag believ inventori level normal
pave way meet market demand go forward strateg
expand paragard direct sale footprint rep favor nejm
studi result competit price pressur persist genet test offset
posit trend fertil solut
guidanc sale guidanc rais midpoint
reflect perform higher fx off-set continu headwind
genet test competit price pressur expect anniversari
manag expect posit contribut paragard start
mid-to-upp singl digit growth driven last year price increas well
new sale forc expans
estim sale estim rise ep
led higher fx forecast sale
ep includ assum increas tax rate
higher estim peer multipl expans pt rise
cooper compani global
medic devic compani focus
primarili
develop
market soft contact lens
compani also market varieti
surgic instrument
analyst certif import disclosur see disclosur appendix
grow ahead market constant currenc
oper margin y/i led contribut
paragard acquisit fx tailwind
len market grow next five year
paragard
better expect margin expans
channel
target price estim cash ep
competit stiffen contact len market estim
above-market contact len growth total sale
growth driven compani specialti len offer
silicon hydrogel daili rollout forecast mid-singl
digit sale growth recent acquir paragard iud
rate share perform valuat
benefit nejm articl invest paragard
competit dynam toughen
slower market growth rebat activ
price target impli approxim multipl cash ep line peer group current-year multipl
risk includ single-us market growth stall competit increas emerg market revenu meaning
cooper compani quarterli incom statement million
non single-us sphere
non single-us sphere
